Envista (NYSE:NVST) Posts Earnings Results, Beats Expectations By $0.05 EPS

Key Points

• Envista beat estimates, reporting $0.36 EPS versus $0.31 expected on $705.5M revenue (up 14.4% YoY), and updated FY2026 guidance to a $1.350–$1.450 EPS range.
• Operationally the quarter showed strength with core sales +9.5% (≈4% normalized), adjusted EBITDA +25% and adjusted EPS +50%, while management authorized an incremental $300M buyback and maintains net debt <1x adjusted EBITDA.
• Near‑term risks include VBP‑related channel destocking in China

Envista (NYSE:NVST - Get Free Report) announced its earnings results on Wednesday. The company reported $0.36 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.05, FiscalAI reports. Envista had a net margin of 2.41% and a return on equity of 7.09%. The business had revenue of $705.50 million during the quarter, compared to analysts' expectations of $680.04 million. During the same period in the prior year, the company earned $0.24 earnings per share. The business's revenue was up 14.4% compared to the same quarter last year. Envista updated its FY 2026 guidance to 1.350-1.450 EPS.

Here are the key takeaways from Envista's conference call:

• Envista reported a strong Q1 with core sales up 9.5% (≈4% normalized excluding extra billing days and Spark deferral), adjusted EBITDA +25% and adjusted EPS +50%, and management reaffirmed full‑year 2026 guidance.
• Leadership expanded shareholder returns, authorizing an incremental $300 million buyback (1.6M shares purchased in Q1) while maintaining a conservative balance sheet with net debt <1x adjusted EBITDA.
• Continued investment and execution — double‑digit increases in sales & marketing and R&D, plus Envista Business System gains — drove a 100 bps gross margin uplift and 120 bps adjusted EBITDA margin improvement.
• Regional and policy risks pose near‑term headwinds, notably VBP-related channel destocking in China causing double‑digit implant declines there, plus geopolitical uncertainty in the Middle East and a looming Q4 billing‑day timing headwind.
• Cash and cost dynamics are mixed — Q1 free cash flow was a seasonal –$16M as CapEx rose for new facilities and tariffs added about $11M of costs, but management still expects roughly 100% free cash flow conversion for 2026.

Envista Stock Performance

NYSE NVST traded down $0.13 during trading hours on Friday, hitting $24.16. 3,006,877 shares of the stock were exchanged, compared to its average volume of 2,853,331. The company has a market cap of $3.94 billion, a price-to-earnings ratio of 59.10, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92. Envista has a 12-month low of $16.41 and a 12-month high of $30.42. The stock has a 50-day moving average of $26.53 and a 200 day moving average of $24.06. The company has a quick ratio of 2.04, a current ratio of 2.38 and a debt-to-equity ratio of 0.47.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on NVST shares. UBS Group upped their target price on shares of Envista from $22.00 to $25.00 and gave the company a "neutral" rating in a report on Tuesday, February 3rd. Morgan Stanley upped their target price on shares of Envista from $19.00 to $21.00 and gave the company an "equal weight" rating in a report on Friday, April 24th. Robert W. Baird upped their target price on shares of Envista from $30.00 to $31.00 and gave the company an "outperform" rating in a report on Thursday. Weiss Ratings raised shares of Envista from a "sell (d)" rating to a "hold (c-)" rating in a report on Tuesday, February 17th. Finally, Evercore reissued an "outperform" rating and set a $33.00 price target on shares of Envista in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $28.83.

Insiders Place Their Bets

In other Envista news, SVP Mischa Reis sold 9,675 shares of the company's stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total transaction of $290,250.00. Following the transaction, the senior vice president directly owned 32,382 shares in the company, valued at approximately $971,460. This represents a 23.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.99% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Prudential Financial Inc. grew its position in Envista by 22.1% during the second quarter. Prudential Financial Inc. now owns 18,785 shares of the company's stock worth $367,000 after buying an additional 3,395 shares during the period. Engineers Gate Manager LP acquired a new position in Envista during the fourth quarter worth about $356,000. PharVision Advisers LLC acquired a new position in Envista during the third quarter worth about $307,000. Abel Hall LLC acquired a new stake in shares of Envista in the fourth quarter valued at approximately $255,000. Finally, Entropy Technologies LP acquired a new stake in shares of Envista in the fourth quarter valued at approximately $224,000.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company's offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista's product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.